Search company, investor...


Founded Year



Growth Equity | Dead

About EnPharma

Developer of drugs based upon small molecule technology initially developed at the University of Ottawa. The company develops small molecules, which target peripheral pathways and gut receptors controlling to regulate food intake and obesity in humans and animals. It focuses on gastrointestinal pharmacology of ‘feed refusal syndrome’.

Headquarters Location

451 Smyth Road, Suite 2230 Level 2, Health Sciences Building

Ottawa, Ontario, K1H 8M5,



Missing: EnPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EnPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

EnPharma Frequently Asked Questions (FAQ)

  • When was EnPharma founded?

    EnPharma was founded in 2000.

  • Where is EnPharma's headquarters?

    EnPharma's headquarters is located at 451 Smyth Road, Suite 2230, Ottawa.

  • What is EnPharma's latest funding round?

    EnPharma's latest funding round is Growth Equity.

  • Who are the investors of EnPharma?

    Investors of EnPharma include Mulligan BioCapital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.